Company profile
Sight Sciences, Inc.
NASDAQ: SGHT · Healthcare · Medical - Devices
#377 of 1,418 Healthcare companies by revenue37th-percentile growth
EA Score
53DFH 54DQ 52GM 49SS 55
v0.1 · 65/100 weight · provisional
↑ market scale, filing timeliness · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$79.6M
Rev growth YoY (TTM)
+1.8%
Net income (FY)
-$38.4M
Employees
186
as of 2026-08-13
Market cap
$450.5M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$77.4M$77.4M2025
Net income-$38.4M-$38.4M2025
Operating income-$37.1M-$37.1M2025
Total assets$115.3M$115.3M2025
Liabilities$51.4M$51.4M2025
Equity$63.9M$63.9M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Surgical Glaucoma98%
Dry Eye2%
By geography
Not disclosed.
The read
What is Sight Sciences, Inc.’s revenue?
Sight Sciences, Inc. booked $77.4M in FY2025 revenue, contracting 3.1% year over year — slower than 63% of Healthcare companies we track, at a -49.7% net margin.
Peers · Healthcare
TELA Bio, Inc.47DEton Pharmaceuticals, Inc.60CVitalhub Corp.77B+Cannara Biotech Inc.76B+CytomX Therapeutics, Inc.63CInterpharm Holdings, Inc.——Neighbors
San Mateo →Key facts
CEOPaul Badawi
SectorHealthcare
IndustryMedical - Devices
HeadquartersMenlo Park, CA
ExchangeNASDAQ: SGHT
Employees186
IPO date2021-07-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.